Overview of Acepak

Quick Facts

Property	Description
Active ingredient	Aceclofenac (INN)
Form	Oral Tablet
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose	Relieving discomfort and managing swelling
Origin	Synthetic (chemically manufactured)

What Type of Medicine is Acepak?

Acepak is a brand name medication that typically contains Aceclofenac, an active ingredient belonging to the widely recognized Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class. NSAIDs are clinically recognized for their capacity to address discomfort. This medicine is a synthetic agent, meaning it is manufactured chemically, and is designed to work systemically, distributing its effects throughout the body.

The active ingredient in Acepak is recognized for having both pain-relieving and strong anti-inflammatory properties. This allows the medicine to help manage discomfort by reducing the physical signs of swelling, heat, and soreness.

Understanding Acepak's Core Composition and Form

Acepak is usually supplied as an oral tablet for convenience, making the oral route the standard method for its administration. This systemic approach allows the medicine to be absorbed into the bloodstream, differentiating it from topical solutions that work only at the application site.

The composition of the tablet includes the single active ingredient alongside various inactive components (such as fillers and coatings). These elements are necessary to ensure the medicine is stable and is released effectively for absorption in the digestive system. Acepak is commonly classified as a prescription-only (Rx) medication, defining its regulated access under medical guidance.

What is Acepak's General Purpose?

The primary general purpose of this medicine is to help manage and relieve overall physical discomfort often associated with swelling and internal irritation. A key function of its class is the ability to help the body counteract the processes that cause pain signals and inflammation.

The action of this medicine is focused on moderating the body's inflammatory response. This helps improve general comfort and mobility by settling the body's over-reaction to irritation or injury.

What side effects are possible with Acepak?

Possible Side Effects and Safety Information

Official regulatory documents classify a medicine’s safety profile by the frequency and type of adverse reactions reported. The most serious and clinically significant risks are detailed as safety restrictions and warnings.

Adverse Reaction Scope

Adverse reactions are classified into categories based on the frequency of occurrence (e.g., Very Common, Common, Uncommon) and grouped by System-Organ-Class (e.g., Gastrointestinal Disorders, Nervous System Disorders).

Serious Adverse Reactions (SARs) are those events that meet specific regulatory criteria, such as resulting in death, being life-threatening, or requiring inpatient hospitalization. Regulatory documentation highlights the risk of Severe Respiratory Depression, which is life-threatening and may occur particularly during the initiation of treatment or following a dosage increase.

Safety Restrictions and Monitoring

Hepatotoxicity (liver damage) is a noted safety risk associated with the acetaminophen component, often linked to total daily dosages exceeding established limits or the use of multiple acetaminophen-containing products.

Population-Specific Safety Considerations are defined in the regulatory information. Use of the opioid component is often contraindicated in pediatric patients under 12 years of age and in adolescents under 18 following specific surgeries (e.g., tonsillectomy/adenoidectomy). Use during pregnancy for an extended period carries a risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. Furthermore, caution is required for patients with pre-existing conditions, such as severe respiratory disease or significant liver or kidney impairment, as these conditions may increase the risk of serious adverse effects.

Concomitant Use Warnings are provided for use with other Central Nervous System (CNS) depressants, including benzodiazepines and alcohol, as this combination significantly increases the risks of profound sedation, severe respiratory depression, coma, and death.

Overdose and Emergency Response

️ Overdose Manifestations and Immediate Action

Acute overdose with the active ingredient Aceclofenac is officially documented to involve symptoms primarily linked to the gastrointestinal and central nervous systems. Documented manifestations can include nausea, vomiting, epigastric pain, headache, and confusion or drowsiness. Hypotension and respiratory depression have also been reported in regulatory sources. Urgent medical attention is required for any suspected overdose or ingestion of a potentially toxic amount, as stated in the prescribing information.

Severe Risks and Supportive Management

Significant poisoning carries a documented risk of severe organ toxicity, including acute renal failure and liver damage. Serious neurological events such as coma and convulsions are also listed as potential complications. The official labeling confirms that no specific antidote is known for this medication.

Management is symptomatic and supportive, focusing on observation and monitoring of renal and liver function for at least four hours following ingestion. Regulatory guidance includes considering the use of activated charcoal or gastric lavage in adults within one hour of ingesting a potentially life-threatening overdose. Furthermore, patients who are elderly or have pre-existing organ impairment are identified as being at the greatest risk for severe overdose complications.

Therapeutic Uses of Acepak

What Acepak Treats: Main Uses and Benefits

Aceclofenac, the active ingredient in Acepak, is commonly used for symptomatic relief across various inflammatory and painful conditions in adults. This medicine is relevant for easing symptoms that interfere with daily functioning, particularly those related to inflammatory or irritative states. It is applied across therapeutic domains to help address symptom clusters that may become intense, specifically easing the persistent joint swelling, physical stiffness, and chronic discomfort.

The medicine is commonly used for conditions such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and for managing acute events like soft tissue injuries, post-procedural pain, and localized episodic discomforts like dysmenorrhea and Gout attacks. Using the medicine in these contexts may help patients cope more steadily with symptom fluctuations by easing distress when symptoms become more noticeable.

Quick Fact: Relief for Inflammation and Pain

Acepak contributes to easing the overall symptom burden of temporary physiological imbalance. It is considered relevant in clinical settings involving acute or disruptive symptom patterns where short-term symptomatic assistance is needed, and may assist with supporting functional stability.

Eligibility and Restrictions for Use

Acepak (Aceclofenac) is subject to strict eligibility rules documented in official regulatory labeling. Use is generally established for adults (typically 18 years and older).

Absolute Contraindications

The medicine is contraindicated in several populations. Individuals must not use Acepak if they have a known hypersensitivity to aceclofenac or other NSAIDs (such as aspirin), or if NSAIDs have previously triggered conditions like asthma or rhinitis. Absolute prohibitions also apply to patients with severe hepatic impairment, severe renal impairment, severe heart failure (NYHA Class II–IV), established ischaemic heart disease, or active/recurrent peptic ulceration or GI bleeding. Acepak is also strictly contraindicated during the third trimester of pregnancy.

Population Restrictions

Use is not recommended in children and adolescents under 18 years of age due to insufficient clinical data. Older adults require careful consideration, and treatment must utilize the lowest effective dosage. The medicine is also not recommended for women who are breastfeeding or those attempting to conceive. Patients with mild to moderate hepatic or renal impairment, or those with inflammatory bowel diseases (e.g., Ulcerative Colitis or Crohn's disease), are restricted to use under strict caution and surveillance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define specific interaction patterns for Acepak (Aceclofenac) based on pharmacokinetic and pharmacodynamic outcomes.

Documented Pharmacodynamic Interactions

This medicine is officially restricted from co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin, as this combination is documented as a contraindication due to a severely increased risk of gastrointestinal bleeding. Similarly, concurrent use with Systemic Corticosteroids, Anti-platelet agents, or Selective Serotonin Reuptake Inhibitors (SSRIs) carries a stated increased risk of gastrointestinal hemorrhage.

Co-administration with oral Anticoagulants (e.g., Warfarin) may officially enhance the anticoagulant effect, requiring close monitoring.

Official Clearance and Exposure Alterations

Aceclofenac may inhibit the renal clearance of substances such as Lithium and Digoxin, resulting in documented increased plasma concentrations of these co-administered agents. Concomitant use with Diuretics or ACE Inhibitors and ARBs may result in a reduced clinical effect of the co-administered drug and an officially stated increased risk of nephrotoxicity or acute renal insufficiency.

Administration with Methotrexate may officially increase plasma levels of methotrexate, increasing the potential for toxicity.

Mandatory Use Constraints

Official labeling specifies a required timing separation for Mifepristone; NSAIDs should not be used for 8–12 days afterward, as this may officially reduce the therapeutic effect. The presence of food is documented to reduce the rate of absorption of Acepak, but does not affect the overall exposure. Regulatory documents caution that alcohol may cause gastric bleeding, which is a consideration for regular consumers.

Mechanism of Action

Modulating Enzyme Signaling to Affect Mediator Synthesis

The action begins by operating within the enzymatic signaling domain through the inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This inhibition occurs with a greater affinity for the COX-2 isoform than for COX-1. By blocking COX-2, the drug interrupts the biosynthesis of lipid mediators, such as prostaglandins. This mechanism modulates a key pathway by decreasing the activity of signaling molecules, resulting in a systemic physiological adjustment to mediator presence.

Suppression of Excitability in the Nociceptive Pathway

The suppression of prostaglandins directly affects the nociceptive signaling pathway by reducing the excitability threshold of peripheral nociceptors. Lowering their concentration modifies these early molecular steps, which shapes the systemic physiological outcome by decreasing the sensitization of nociceptors. This mechanism is complemented by the action of its active form, which further acts as a suppressor of specific pro-inflammatory cytokines.

Modulating Connective Tissue Metabolism

Beyond its core enzyme blockade, the drug's mechanism involves the domain of tissue matrix regulation. The active metabolite of Aceclofenac specifically acts by suppressing enzymes that degrade cartilage, known as Matrix Metalloproteinases (MMPs). This action restricts the influence of catabolic activity, contributing to the modulation of the pathway governing connective tissue stability.

Dosage and Administration Information

Acepak is administered by the oral route, primarily supplied as a 100 mg film-coated tablet for use in adults. The standard regimen for the conventional tablet is a total daily dose of 200 mg, usually achieved by taking 100 mg twice daily—one tablet in the morning and one in the evening. This divided use is intended for maintaining consistent blood levels.

The medicine is instructed to be taken with or immediately after food; ingestion with food may slow the rate of absorption but is generally recommended. Tablets must be swallowed whole with liquid and should not be crushed or chewed, as this action can compromise the integrity of the coating and affect drug release.

The clinical principle for use is that the lowest effective dose should be utilized for the shortest duration necessary to manage symptoms. For patients using the medicine over an extended period, it is standard to perform a periodic re-evaluation of the necessity for continued treatment.

Dosing adjustments are stipulated for specific populations. For instance, patients with mild to moderate hepatic impairment are typically instructed to begin treatment with a reduced total daily dose of 100 mg taken once daily. Conversely, while no general dose change is recommended for older adults, the medicine is not recommended for use in children due to a lack of sufficient clinical data in this specific population. If a standard 100 mg dose is missed, it should not be doubled, and the patient should resume the regular schedule with the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Acepak

Evidence for use in Osteoarthritis (OA)

Research has explored the role of Aceclofenac in conditions characterized by functional limitations, specifically Osteoarthritis (OA). These investigations were typically short-term Randomized Controlled Trials (RCTs), often lasting between 4 and 12 weeks, applied in studies examining patient-reported experiences in adults. The outcomes related to physical discomfort that were monitored included Pain Intensity (using scales like VAS) and outcomes reflecting daily functioning (such as the WOMAC Index).

Studies reported measurements where patterns were observed in measured outcomes related to physical discomfort and daily functioning in the active group compared to placebo over the duration of the trials. Some comparative trials described patterns where the measurements were similar to those observed with other commonly studied medicines. However, long-term functional outcomes and the persistence of symptomatic changes beyond six months are not well-characterized, and some evidence reports noted high variability in the measured outcomes related to daily functioning.

Evidence for use in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)

Research examined Aceclofenac in studies involving conditions such as Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). Research for both conditions consisted primarily of short-to-medium-term (around 12 weeks) RCTs. In these studies, outcomes linked to inflammatory or irritative states were monitored, including joint tenderness, swelling, duration of morning stiffness, and spinal mobility measurements.

Studies conducted during periods of increased symptom activity reported how symptoms evolved, with changes measured were evaluated against those observed in active comparator groups. The research focused entirely on symptomatic measurements, and trials reported findings described variations in scores for joint pain, tenderness, and swelling relative to baseline measurements over the observation period.

Evidence for use in Acute and Localized Pain States

Aceclofenac was studied for short-term symptom changes in conditions associated with acute or disruptive episodes, focusing on acute musculoskeletal and localized pain. Research explored symptom changes, typically over very short time intervals, sometimes up to 10 days. The outcomes describing episodic or acute changes that were measured included the speed and degree of pain reduction. Findings describe patterns observed in these studies where patterns in pain intensity scores were documented. Reported analgesic measurements were compared to common comparators in these acute pain settings.

Identified Gaps and Areas of Uncertainty in Research

A key uncertainty is the lack of research exploring the long-term patterns of disease progression in patients using Aceclofenac for conditions like Rheumatoid Arthritis or Ankylosing Spondylitis; existing studies provide limited insight into this area. Additionally, findings were mixed across some studies related to functional capacity measurements in Osteoarthritis, and evidence quality varies across studies. Overall, research provides context but not individual predictions, and the results apply only to the specific conditions under which they were conducted.

Key Studies & References

Single dose oral aceclofenac for postoperative pain in adults (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Acepak (FAQ)

Q: Does Acepak come in different strengths?

Regulatory documents primarily describe Acepak in the form of an oral 100 mg film-coated tablet. When seeking information on this medicine, official sources typically reference this specific strength and formulation.

Q: Can Acepak be used for conditions other than what it is approved for?

Official information defines Acepak's purpose for the specific conditions that the medicine has been studied and approved to address. Regulatory documents describe the medicine's use for the specific indications that it has been studied and approved to address.

Q: Is Acepak considered a narcotic or controlled substance?

Acepak belongs to the pharmacological class known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Based on this classification, it is not listed as a controlled substance by regulatory agencies.

Q: Is Acepak a generic or a brand-name medicine?

Acepak is designated as a brand name medication. The actual active compound it contains is called Aceclofenac, which is the generic name for the substance.

Q: How quickly does Acepak start working?

The medicine's active ingredient is absorbed according to its pharmacokinetic profile. This profile is a factor in determining the dosing schedule to help achieve and maintain consistent levels of the active ingredient.

Q: How long do the effects of Acepak last?

The active ingredient in Acepak has a reported biological half-life of approximately 4 to 4.3 hours. This half-life, which refers to the time it takes for half of the drug to be eliminated from the body, is a factor in the recommended twice-daily dosing regimen to help maintain consistent levels.

Q: Will Acepak show up on a standard drug test?

Acepak is a Nonsteroidal Anti-inflammatory Drug (NSAID). Standard drug tests are typically designed to screen for controlled substances, such as certain opioids or amphetamines, and they do not usually include NSAIDs in their screening panels.

Q: Does Acepak cause weight gain or loss?

When reviewing the undesirable effects reported in official documents, weight increase is described as a reported adverse reaction in rare cases. This indicates that it is a very rare event, observed in less than 1 in 1,000 patients.

Q: Does Acepak affect sleep patterns?

Regulatory documents note that effects such as dizziness and drowsiness have been reported as occasional undesirable effects (incidence typically less than 5%). These types of effects may potentially interfere with normal sleep patterns.

Q: Does Acepak have an impact on blood pressure?

Hypertension (high blood pressure) and oedema (fluid retention) have been reported in association with NSAID treatment. Official warnings document the need for caution when used by patients with pre-existing heart conditions.

Q: Is there a risk of dependency or withdrawal with Acepak?

Acepak is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not associated with the risk of dependency or withdrawal syndromes that are typically linked to controlled substances.

Q: Are there different forms of Acepak (e.g., tablet, capsule, liquid)?

Regulatory documents specify that the medicine is supplied for oral use as a 100 mg film-coated tablet. Official product information typically details only the use of this specific tablet form.

Q: Why is Acepak sometimes called a 'selective' medicine?

Acepak's active ingredient is described as a selective inhibitor because of its mechanism of action. It demonstrates a greater affinity for the Cyclooxygenase-2 (COX-2) enzyme than for COX-1.

Q: What if Acepak is exposed to heat or direct sunlight?

Official storage guidelines require the medicine to be stored below 30 C in a dry place. The medicine is required to be kept protected from light by remaining in the original package to maintain its integrity.

Q: Are allergic reactions common with Acepak?

The official documentation lists hypersensitivity to Aceclofenac or other NSAIDs as a contraindication. Serious allergic skin reactions have been reported very rarely in association with NSAID use, typically occurring early in treatment.

Q: Can Acepak cause stomach problems like nausea or upset?

Gastrointestinal issues are among the most frequently observed effects in clinical reports. Regulatory documents list reactions like nausea, diarrhea, and constipation as occasional side effects, observed in typically less than 5% of patients.

Q: How is Acepak's purpose described in official regulatory documents?

The primary general purpose of this medicine, according to official documents, is to help manage and relieve overall physical discomfort often associated with swelling and internal irritation. Its function is described as moderating the body's inflammatory response.

Q: Does Acepak cause drowsiness or affect driving?

Regulatory warnings document that the medicine may cause dizziness, blurred vision, or drowsiness. Regulatory documents state that if a patient experiences these effects, they are cautioned against driving or operating machinery.

Q: What is the recommended way to stop taking Acepak?

Official documents state that the necessity for continued treatment is subject to periodic re-evaluation. Furthermore, the medicine must be discontinued if serious adverse events occur, such as signs of gastrointestinal bleeding or persistent abnormal liver function tests.

How should Acepak be stored and disposed of?

How to Store and Dispose of Acepak (Aceclofenac Tablets)

Official regulatory guidelines define specific storage and disposal requirements for Acepak to maintain product stability and safety.

Storage Conditions

Detail	Requirement
Temperature	Store below 30 C in a dry place.
Protection	Keep the tablets protected from light by storing them in the original package.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Detail	Requirement
General Rule	Any unused product or waste material must be disposed of in accordance with local requirements.
Environmental	Do not dispose of the tablets via wastewater or household waste, as the drug is toxic to aquatic life.

These mandated conditions ensure the integrity of the product throughout its 36-month labeled shelf-life.

Acepak